מתמחים - האיגוד הישראלי לרפואה דחופה

מתמחים - האיגוד הישראלי לרפואה דחופה

By מתמחים – האיגוד הישראלי לרפואה דחופהMedicineHealth & Fitness
Download on the App Store

מתמחים - האיגוד הישראלי לרפואה דחופה episodes

  • PODCAST: Pediatric Respiratory Emergencies: Beyond Viral Season
    • Written by Anand Swaminathan
    • REBEL Cast, REBEL Core, REBEL EM
    • Medical Category: Pediatrics, Thoracic and Respiratory
    • Asthma, Bronchiolitis, croup, Emergency Medicine, Pediatrics, PEM, REBEL Core Cast, respiratory distress, stridor, wheezing
      • December 4, 2025
        • Introduction
        • Recognizing Respiratory Patterns
        • Localizing Sounds for Accurate Diagnosis
        • Tailoring Treatment for Effective Results
        • Intervening with Severe Asthma
        • Navigating the Zebras of Respiratory Cases
        • Conclusion

          Introduction

          Welcome to the Rebel Core Content Blog, where we delve into crucial knowledge for emergency medicine. Today, we share insightful tips from PEM specialist Dr. Elise Perelman, shedding light on respiratory challenges in infants, toddlers, and young children during the viral season. Understanding that most cases involve typical viruses, we aim to equip you with diagnostic pearls to identify more serious pathologies.

          Recognizing Respiratory Patterns

          Pearl #1: Look at Your Patient

          Begin exams from the doorway. Observing patterns such as accessory muscle usage can reveal a patient’s respiratory effort. Specify whether the work of breathing occurs during inspiration, expiration, or both. Inspiratory work indicates difficulty getting air in, while expiratory work suggests trouble pushing air out. Silent tachypnea may point to other issues, like acidemia or pneumothorax.

          Localizing Sounds for Accurate Diagnosis

          Pearl #2: Localize the Sound

          Breathing noises signal varied respiratory issues. Stridor, often heard on inspiration, results from obstructions above the thoracic inlet. Conversely, wheezing, generally linked to exhalation, indicates obstructions in the lower airways. Watch for signs like ‘silent chest’—a dangerous, severe obstruction, and distinguish grunting as a bodily mechanism to prevent alveolar collapse. Correctly identifying the sound assists in determining the appropriate intervention.

          Tailoring Treatment for Effective Results

          Once a sound is localized, treatments vary. We explore Soder from nasal congestion, typically needing supportive care and suctioning. Stridor from conditions like croup is eased with interventions to reduce airway swelling, such as steroids or inhaled epinephrine. Conversely, wheezing in infants is often due to bronchiolitis—not bronchospasms—and over-treatment is to be avoided. Supportive measures including suction, hydration, and oxygen are preferred unless improvement warrants bronchodilators.

          Intervening with Severe Asthma

          In severe cases of asthma or bronchiolitis, where standard at-home treatments fail, immediate adjunct therapies like intramuscular epinephrine become essential. Administering this quickly can alleviate obstruction when inhalants aren’t effective due to low air movement.

          Navigating the Zebras of Respiratory Cases

          When recognizing Zebras—uncommon cases overshadowed by routine diagnoses—remain vigilant for histories or presentations that don’t conform. Conditions like pneumonia, bacterial tracheitis, and even myocarditis may mimic more common issues.

          Conclusion

          As attending physicians, our role extends beyond conventional treatment—it’s about discerning the atypical from the typical. Dr. Perelman urges continual reassessment, emphasizing reliance on observational skills as much as technological aid. Keeping keen on respiratory nuances ensures we catch those outlier cases, paving the way for adept medical care despite the overwhelming prevalence of viral infections.

           

          The post PODCAST: Pediatric Respiratory Emergencies: Beyond Viral Season first appeared on האיגוד הישראלי לרפואה דחופה.

          21 min
        • PODCAST: EM Quick Hits Pediatric Urinary Retention & Acute Transverse Myelitis, Post-Dural Puncture Headache, Med Mal Cases: Clenched Fist Injury, IV Thrombolysis for Minor Stroke, EM Leadership Spotlight #4
          “This learning material is sourced from Emergency Medicine Cases  and has been published here with permission as per Creative Commons copyright.” 
          Topics in this EM Quick Hits podcast

          Deborah Schonfeld on pediatric urinary retention & acute transverse myelitis (01:27)

          Jesse McLaren on Occlusion MI Diagnosis (24:44)

          Matthew McArthur on post-dural puncture headache (31:34)

          Joseph Yasmeh on Med Mal Cases: clenched fist injury (42:42)

          Brit Long on IV thrombolysis for minor strokes (59:27)

          Victoria Myers & Lauren Westafer on mentorship and what it means to be a physician leader (1:11:34)

          Podcast production, editing and sound design by Anton Helman

          Podcast content, written summary & blog post by Brandon Ng, edited by Anton Helman, December, 2025

          Cite this podcast as: Helman, A. Schonfeld, D. McLaren, J. McArther, M. Yasmeh, J. Long, B. Myers, V. Westafer, L. EM Quick Hits 69 – Pediatric Urinary Retention & Acute Transverse Myelitis, Post-Dural Puncture Headache, Med Mal Cases: Clenched Fist Injury, IV Thrombolysis for Minor Stroke, EM Leadership Spotlight #4. Emergency Medicine Cases. December, 2025. https://emergencymedicinecases.com/em-quick-hits-month-year/. Accessed December 3, 2025.

          Pediatric Urinary Retention & Acute Transverse Myelitis
          Definition of urinary retention in pediatrics

          Inability to void at least 12 hours, no urine output for 12 hours, greater volume of urine in the bladder expected for age, or palpable bladder distension.

          Max bladder capacity in mL = age + 2 x 30 (for <12 years of age)
          Pediatric urinary retention history taking tips
          • Can be reported as feeling that the child is “holding urine”, unable to fully empty bladder, or frequent bathroom trips with weak stream.
          • May have significant abdo pain, abdo/bladder distension, restlessness/irritability.
          • Try to differentiate from oliguria vs. retention.
          • Differential diagnosis of pediatric urinary retention
            • Infectious/inflammatory: UTI/cystitis, balanitis/balanoposthitis, vulvovaginitis.
            • Obstructive: Phimosis, meatal stenosis, labial adhesions, urethral strictures, posterior urethral valves, external (intrabdominal or pelvic) compression, hematometrocolpos (vaginal/uterine accumulation of blood due to obstruction), constipation.
            • Postoperative/anesthesia
            • Dysfunctional urine voiding: behavioral, lack of coordination between bladder and urethral sphincter muscle.
            • Neurogenic: interruption at any level from brain to spinal cord to peripheral nerves.
              • Spinal cord:
                • Compressive: spinal tumors (e.g. ependymomas, astrocytoma), epidural abscesses, herniated discs, hematoma.
                • Inflammatory: acute transverse myelitis, GBS.
                • Malformation: spinal bifida, tethered cord.
                • Medications: anticholinergics/antihistamines, sympathomimetics (often in decongestants).
                • Clinical pearls for pediatric urinary retention
                  • Counsel parents to let patient urinate within warm water; decreases direct contact of acidic urine with inflamed or irritated tissue and can reduce withholding behavior.
                  • Unexplained urinary retention is always concerning: consider neurologic pathologies if other tests are negative.
                  • Pediatric acute transverse myelitis
                    • Rare, inflammatory, demyelinating disorder of the spinal cord.
                    • Highest incidence between 10-40 years of age, with 20% occurring in the pediatric population.
                    • Etiology: idiopathic (post-infectious/autoimmune process), secondary (associated with active infections, systemic inflammatory conditions, connective tissue disorders), or part of demyelinating or CNS condition (e.g. MS, acute disseminated encephalomyelitis).
                    • Clinical features of transverse myelitis
                      • Typically presents over hours to days.
                      • Affects transverse section of one or more levels of the spinal cord with motor/sensory/autonomic dysfunction below the level of the lesion in a myelopathic distribution.
                        • Motor: Rapidly progressive paraparesis/paraplegia.
                        • Sensation: reduced or absence sensation below the affected level, back pain, dysesthesia.
                        • Autonomic: bowel or bladder incontinence or retention.
                        • Often missed on initial visit, with patients returning to ED with progressive symptoms.
                        • Bottom line: Urinary retention may present variably in pediatric patients. In pediatric patients with otherwise unexplained urinary retention, consider neurogenic causes of urinary retention in patients.

                          Expand to view reference list

                          Triptych Approach to Occlusion MI Diagnosis
                          Classic STEMI Criteria for OMI
                          • LR+ = 12.5: STEMI criteria present = OMI becomes much more likely even if patient does not have classic symptoms.
                          • LR− = 0.59: STEMI criteria absent only slightly lowers probability = cannot rule out OMI in higher-risk presentations.
                          • The “Triptych” Approach to Improve Accuracy of OMI Diagnosis
                            1. Determining pre-test likelihood for OMI based on history and assessment
                                • A = anginal equivalents (not just chest pain)
                                • C = continuous vs resolved symptoms
                                • S = stability (hemodynamic)
                                  1. ECG
                                      • Advanced OMI signs perform better (LR+ = 14, LR− = 0.23): e.g. Modified Sgarbossa criteria increases likelihood of OMI in LBBB, or lack of reciprocal AVL change decreases OMI likelihood when there is borderline inferior ST elevation
                                        1. POCUS
                                            • Patients can have OMI without any ECG changes
                                            • Use POCUS to look for regional wall motion abnormality: especially with high pre-test likelihood but subtle/non-diagnostic ECG
                                            • Bottom line: ECG represents only one aspect of the clinical picture. Do not interpret ECGs using STEMI criteria alone. Consider POCUS to enhance diagnosis of OMI.

                                              Expand to view reference list

                                              Deeper Dive and practice ECGs: ECG Cases 57 Art of Occlusion MI Part 5 – Clinical-ECG-POCUS Triptych

                                              Register for Dr. McLaren’s HEARTS ECG Course to master your ECG interpretation skills.

                                              Post Dural Puncture Headache (Post LP Headache) Recognition, Prevention and Management

                                              Consider post-dural puncture headache in any patient with new positional headache that occurs within five days of a dural puncture.

                                              Clinical features of post dural puncture headache
                                              • Symptom severity ranges from mild to debilitating
                                              • Positional headache after recent lumbar puncture within 5 days
                                              • Relieved by lying down, intolerable pounding headache when upright
                                              • Associated neck & shoulder stiffness/pain, tinnitus, visual disturbances (diplopia), and dizziness/vertigo
                                              • Risk factors for post dural puncture headache
                                                • Patient: younger age and female sex.
                                                • Procedural: Size and type of spinal needle (larger needles and sharper bevel increases risk).
                                                • Prevention of post dural puncture headache
                                                  • Routine use of non-cutting spinal needles for lumbar puncture for all population (Grade A evidence, high level of certainty) (Uppal et al. 2023).
                                                  • If using cutting needle, use narrowest gauge possible and position needle with bevel aligned in longitudinal axis of the spine.
                                                  • Investigations for suspected post dural puncture headache
                                                    • Neuroimaging: not routine, consider if focal neurological deficits, vision changes, altered GCS or seizures, or suspecting an alternative diagnosis.
                                                    • Treatment of post dural puncture headache
                                                      • Symptoms typically self-resolves within 1 week (time taken for punctured dura to heal).
                                                      • Non-pharmacologic:
                                                        • Support supine position for comfort.
                                                        • Maintain adequate hydration (preferably oral).
                                                        • Pharmacologic:
                                                          • NSAID or acetaminophen, or short course of opioids.
                                                          • There is some evidence to suggest that caffeine up to 900 mg per day if presenting <24h of symptom onset may improve symptoms
                                                          • Procedural:
                                                            • Epidural blood patch (definitive treatment): 20mL of patient’s own blood injected into epidural space at the level of the dural puncture. Performed by anesthesia.
                                                            • Temporary local nerve block, including occipital nerve block (Uppal et al. 2023).
                                                            • Temporary transnasal sphenopalatine block: topical lidocaine/bupivacaine applied into both nostrils until contact made with posterior pharynx x10-15min (Uppal et al. 2023).
                                                            • Expand to view reference list

                                                              MedMal Cases: Clenched Fist Injury – Fight Bite

                                                              This case involves an young adult male who presents with an injured hand that occurred when “messing around with some friends” when a brick “fell directly onto the back of his left hand”. The case highlights the importance of spotting the disconnect between the patient’s story and the presenting wound.

                                                              Clenched Fist Injury (Fight Bite) = consider in any laceration over the dorsal aspect of MCP or PIP joints, usually in the dominant hand.

                                                              Pathophysiology of clenched fist injury (fight bite)

                                                              • Fist-to-tooth contact – inoculation of human oral flora often into the joint space.
                                                              • When hand relaxes – skin and tendon wound retract, sealing bacteria inside the joint fluid.
                                                              • Synovial fluid acts as a nutrient-rich medium – rapid, severe joint infection despite benign skin findings.
                                                              • Red-flag exam: Pain with passive finger motion = deep infection (infectious tenosynovitis/septic arthritis) until proven otherwise.

                                                                Investigations for suspected clenched fist injury (fight bite)

                                                                • X-ray to rule out fracture or foreign body. Does not rule out tendon/ligament/joint capsule injury or infection.
                                                                • Critical Error #1: During wound care (including anesthetizing, irrigation and exploration), the tendon sheath was “frayed”, but the wound was closed with sutures.

                                                                  • Frayed tendon sheath – direct signs inoculation injury likely into the joint space.
                                                                  • Fight bite should be left open to drain.
                                                                  • Critical Error #2: Cefazolin/cephalexin were given for the skin and soft tissue injury.

                                                                    • Inadequate coverage for human bite organisms (fastidious gram-negative rods, Eikenella corrodens (often multi-drug resistant), Strep viridans, anerobes.
                                                                    • Tetanus booster (if not up to date) required given likely contaminated environment
                                                                    • Typical antibiotic first line: Amoxicillin-clavulanate
                                                                    • Critical Error #3: Patient was discharged with a splint and told to follow-up with a plastic surgeon in several days.

                                                                      • Recommended follow up is re-evaluation within 24 hours (in the ED or by plastics).
                                                                      • Additional considerations: An accurate diagnosis and reasonable plan may fail if the patient can’t access treatment.

                                                                        • Give first antibiotic dose in ED.
                                                                        • Choose affordable/generic options.
                                                                        • Consider involving social work/case management to ensure the patient can obtain and start meds promptly.
                                                                        • Bottom line: Trust the injury pattern not the story, injury over the knuckles of young person = clenched fist injury until proven otherwise. For bite wounds: irrigate thoroughly, do not suture primarily, splint hand in position of function, follow-up within 24-48 hours, and preferred antibiotic is amoxicillin-clavulanate. Acknowledge and address barriers of care to help ensure that patient gets the treatment you prescribe.

                                                                          *This case was obtained from Dr. Mike Weinstock’s EM Boucebacks series of closed legal cases

                                                                          IV Thrombolysis for Disabling Minor Stroke

                                                                          To address an EM Caser’s concern about the questionable evidence for IV thrombolysis in patients who present within 4.5 hours of symptom onset with a minor stroke (defined as NIHSS ≤5) but their stroke is deemed disabling, we asked Brit Long for an evidence-based deep dive…

                                                                          Current Guidelines

                                                                          • AHA and ASA: IVT within 4.5h for patients with ischemic stroke.
                                                                          • Canadian Stroke Best Practice Recommendations (2022): eligible patients with disabling ischemic stroke, who can receive IVT (alteplase/tenecteplase) within 4.5h of stroke symptom onset time/last known well time should be offered IVT (Strong recommendation; High quality of evidence).
                                                                          • ACEP clinical policy (2024):
                                                                            • Stroke patients who are candidates for both mechanical thrombectomy and IVT, IVT should be offered and may be given prior to mechanical thrombectomy, and that if IVT will be administered, it should be given within 4.5h from symptom onset (Level B recommendation).
                                                                            • When feasible, shared decision making between the patient/surrogate and the health care team should include a discussion of potential benefits and harms prior to the decision whether to administer IVT (Level C recommendation; Consensus recommendation).
                                                                            • Literature on IVT in disabling strokes:

                                                                              • Several meta-analyses have attempted to pool data on RCT data, but study limitations (including heterogeneity among trials, selective emphasis on trials claiming IVT benefit, individual trial bias, financial conflicts of interest, trials stopping early, low power) limit conclusions that can be drawn.
                                                                              • Evidence supporting IVT
                                                                                Evidence against IVT
                                                                                2 trials between 1995 to 2012 have demonstrated benefit: 

                                                                                ·       NINDS II (1995): n = 333, 12% benefit with IVT in 3 hours.

                                                                                ·       ECASS III (2008): n = 821, 8% benefit with IVT in 3-4.5 hours.

                                                                                 

                                                                                Re-analyses of NINDS II and ECASS III suggest that baseline imbalance in stroke severity likely responsible for the difference in outcome supporting IVT. Accounting for differences, there is likely no benefit with IVT and potential risk of harm (Hoffman and Schriger 2009, Alper et al. 2020).
                                                                                Fragility index was 3 for NINDS II and 1 for ECASS III.
                                                                                Most RCTs have not found a benefit with IVT.
                                                                                5 RCTs suggest increased mortality with IVT in stroke (12-16% higher risk).

                                                                                Literature on IVT in non-disabling stroke:

                                                                                • Several available studies comparing IVT to antiplatelet therapy (aspirin +/- clopidogrel/ticagrelor): PRISMS trial (2018), ARAMIS trial (2023), TEMPO-2 trial (2024) and PUMICE trial (2024).
                                                                                • A 2025 meta-analysis found no improvement in excellent recovery with thrombolysis, but there were lower odds of 90-day independence with thrombolysis (OR 0.7, ARD 2.5%, NNH 40) and an increased mortality with thrombolysis (OR 2.4, ARD 1.5%, NNH 66)
                                                                                  • Limitations: heterogeneity with differing definitions of disabling symptoms, agents, time windows for treatment, routine care strategies, concomitant interventions, follow-up times.
                                                                                  • Trials did not enroll patients with strokes presenting with isolated dysarthria, ataxia, facial weakness, sensory symptoms, and other isolated symptoms not captured by the NIH stroke score.
                                                                                  • Overall, evidence suggest that risk of IVT outweigh benefits in patients with non-disabling strokes.
                                                                                  • Optimizing practice:

                                                                                    • Define disability in strokes based on the individual patient rather than on the NIHSS.
                                                                                    • For nondisabling strokes, current data strongly support antiplatelets and risk factor modification, not thrombolysis.
                                                                                    • In disabling stroke, legal implications of not giving thrombolytics may outweigh risk of complications from IVT.
                                                                                    • Follow your local institutional protocols on IVT in stroke, and ensure neurology is on board.
                                                                                    • Present purported risks and benefits of IVT to patients/family, used shared decision making, and document the discussion.
                                                                                    • Bottom line: Evidence overall suggests that risk of IVT may outweigh benefits in patients with minor stroke, however for disabling minor strokes, IVT should be offered. Consider legal implications of not giving IVT in disabling minor strokes. Reference your local institutional protocols on IVT for stroke.

                                                                                      For further listening on referenced EMCases episodes and Dr. Katie Lin’s take on the evidence for thrombolysis is disabling minor stroke in the comments sections: Ep 208 Paradigm Shift in Ischemic Stroke Management Part 1: Disabling Strokes and Ep 209 Nondisabling Stroke Recognition and Management.

                                                                                      Expand to view reference list

                                                                                      1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418.  Epub 2019 Oct 30. Erratum in: Stroke. 2019 Dec;50(12):e440-e441.
                                                                                      2. American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Thrombolytics; Lo BM, Carpenter CR, Milne K, Panagos P, Haukoos JS, Diercks DB; Members of the American College of Emergency Physicians (ACEP) Clinical Policies Committee (Oversight Committee); Diercks DB, Anderson JD, Byyny R, Carpenter CR, Friedman BW, Gemme SR, Gerardo CJ, Godwin SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Mattu A, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Thompson JT, Tomaszewski CA, Trent SA, Valente JH, Westafer LM, Wall SP, Yu Y, Lin MP, Finnell JT, Schulz T, Vandertulip K. Clinical Policy: Use of Thrombolytics for the Management of Acute Ischemic Stroke in the Emergency Department. Ann Emerg Med. 2024 Dec;84(6):e57-e86.
                                                                                      3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995 Dec 14;333(24):1581-7.
                                                                                      4. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29.
                                                                                      5. Hoffman JR, Schriger DL. A graphic reanalysis of the NINDS Trial. Ann Emerg Med. 2009 Sep;54(3):329-36, 336.e1-35. doi: 10.1016/j.annemergmed.2009.03.019. Epub 2009 May 23. PMID: 19464756.
                                                                                      6. Alper BS, Foster G, Thabane L, Rae-Grant A, Malone-Moses M, Manheimer E. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. BMJ Evid Based Med. 2020 Oct;25(5):168-171.
                                                                                      7. Doheim MF, Nguyen TN, Xiong Y, Chen HS, Bhatt NR, Wang Y, Nogueira RG. Meta-Analysis of Randomized Controlled Trials on IV Thrombolysis in Patients With Minor Acute Ischemic Stroke. 2025 Aug 12;105(3):e213863.
                                                                                      8. Long B, Gottlieb M. Intravenous Thrombolysis for Minor Acute Ischemic Stroke. Acad Emerg Med. 2025 Sep 4.
                                                                                      9. https://first10em.com/thrombolytics-for-acute-ischemic-stroke-nnt-evidence-review/
                                                                                      10. https://rebelem.com/thrombolysis-in-acute-ischemic-stroke-now-we-have-no-positive-rcts/
                                                                                      11. https://thesgem.com/2020/07/sgem297-tpa-advocates-be-like-never-gonn
                                                                                      12. The post PODCAST: EM Quick Hits Pediatric Urinary Retention & Acute Transverse Myelitis, Post-Dural Puncture Headache, Med Mal Cases: Clenched Fist Injury, IV Thrombolysis for Minor Stroke, EM Leadership Spotlight #4 first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                        1 hr 33 min
                                                                                      13. PODCAST: Understanding QTc Prolongation: Causes, Risks, and Management
                                                                                        Key Points
                                                                                          •  Prolonged QTc raises risk of torsades de pointes
                                                                                          •  Correct for heart rate: QTc > 440 ms (men) or > 460 ms (women); > 500 ms = high TdP risk.
                                                                                          •  Common culprits: Methadone, ondansetron, macrolides, fluoroquinolones, antipsychotics.
                                                                                          •  Prevention: Check & replete K, Mg, Ca and avoid QT-prolonging meds when possible.
                                                                                          •  If TdP develops: Defibrillate + IV magnesium and stop offending agents.
                                                                                          • Introduction

                                                                                            The QT interval is a vital part of ECG interpretation, reflecting the heart’s electrical recovery after each beat. When prolonged, it can set the stage for torsades de pointes. Understanding how to measure and correct the QT interval, identify high-risk medications, and act quickly when TdP occurs is essential for every clinician. This guide walks you through the physiology, interpretation, common causes, and emergency management of QTc prolongation to keep your patients safe.

                                                                                            Definition and Physiology
                                                                                            • QT evaluation is a fundamental component of EKG analysis. The QT interval reflects the time from ventricular depolarization and contraction through ventricular repolarization and relaxation.
                                                                                            • Clinically, QT prolongation increases the risk of torsades de pointes (TdP) – a form of polymorphic ventricular tachycardia (a non-perfusing rhythm) that is classically described as a pattern of “twisting points” or alternating amplitudes. This occurs when a premature ventricular contraction leads to an R on T phenomenon during the repolarization period.
                                                                                            • The differential for QT prolongation is long and varied: congenital long QT, electrolyte disturbances (hypoK, hypoMg, hypoCa), hypothermia, myocardial ischemia, and increased intracranial pressure. Moreover, a whole host of xenobiotics can prolong the QT interval: methadone, anti-microbials, anti-emetics, anti-psychotics, and anti-dysrhythmics.
                                                                                            • ECG Interpretation
                                                                                              • The QT interval must be interpreted in conjunction with the patient’s heart rate. The QT interval with shorten in the context tachycardia and length in the context of bradycardia. In other words, tachycardia is protective when evaluating the patient with prolonged QT.
                                                                                              • With that in mind, many EKG machines will calculate a corrected QT interval or QTc. The QTc is a standardized way to account for variations in heart rate so clinicians are able to compared QT intervals at different heart rates over time and thus calculate risk.
                                                                                              • Generally, a QTc is considered prolonged if greater than 440ms in males or 460ms in females. Once the QTc > 500msec, the risk of TdP increases 2-3 fold.1
                                                                                              • A variety of different correction formulas exist: Bazett, Fridericia, Hodges, Framingham, Rautaharju.
                                                                                              • Manually, the QT interval should be measured from the beginning of the QRS complex to the end of the T wave – and thus should be measured in leads where all portions can be visualized, most frequently lead II or V5/V6. Ideally, the QT interval should be average over 3 or more beats.2 To determine the end of the T wave, a tangent line should be drawn through the maximum slope of the T wave – the point at which this line crosses the isoelectric line is the end of the T wave.3
                                                                                              • Commonly Used QTc Prolonging Medications
                                                                                                • Methadone: particularly concerning because not only does it inherently prolong QT but also induces a bradycardia
                                                                                                • Antiemetics: Ondansetron
                                                                                                • Macrolides: azithromycin, erythromycin, clarithromycin
                                                                                                • Fluroquinolones: ciprofloxacin, levofloxacin
                                                                                                • Antipsychotics: Haloperidol, Olanzapine
                                                                                                • Management
                                                                                                  • Prevention is key!
                                                                                                    • Assess electrolytes (Mg, Ca, K) and replete as needed
                                                                                                    • Telemetry Monitoring
                                                                                                    • If patient happens to fall into TdP, initiate ACLS with immediate defibrillation and magnesium.
                                                                                                    • Withdrawal of offending agents.
                                                                                                    • References
                                                                                                      1. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010 Mar;121(8):1047-1060.
                                                                                                      2. Postema PG and Wilde AAM. The measurement of the QT interval. Curr Cardiol Rev. 2014 Aug;10(3): 287-294.
                                                                                                      3. https://litfl.com/qt-interval-ecg-library/
                                                                                                      4. The post PODCAST: Understanding QTc Prolongation: Causes, Risks, and Management first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                        15 min
                                                                                                      5. PODCAST: Nondisabling Stroke Recognition and Management
                                                                                                        “This learning material is sourced from Emergency Medicine Cases  and has been published here with permission as per creative commons copyright” 

                                                                                                        Nondisabling stroke is where Emergency Medicine earns its keep. The threats are quieter, the windows are wider, and the misses—especially in younger and female patients—are more common. In this Part 2 or our 2-part podcast update on ED stroke management with Dr. Katie Lin and Dr. Walter Himmel we explore non-disabling strokes, where symptoms are mild enough that patients can continue daily activities if deficits persist. Yet, non-disabling does not mean benign. Nondisabling strokes occupy the same ischemic continuum as high risk TIAs and carry a substantial risk of early recurrent disabling stroke. In this EM Cases podcast we answer questions such as: Which patients with non-disabling stroke can safely be discharged from the ED with prompt follow-up and which require urgent investigation or admission? Which stroke mimics do we need to be on the look out for and how do we identify them at the bedside? How dangerous is thrombolysis in a patient with presumed stroke who turns out to be a stroke mimic? What are the key distinguishing features between a stroke and functional neurologic disorder? What are the most common causes of stroke in young people that we commonly miss? How does stroke etiology dictate the management pathway? What are the indications for carotid endarterectomy in patients with nondisabling stroke and what is the ideal timing of the endarterectomy? When is dual antiplatelet therapy vs single antiplatelet therapy vs anticoagulant therapy indicated? What is the best medication strategy for the patient on a DOAC for atrial fibrillation who presents to the ED with a nondisabling stroke? For patients not on a DOAC for atrial fibrillation who come in with a stroke, when is it safe to start anticoagulation? and many more…

                                                                                                        Podcast production, sound design & editing by Anton Helman; Voice editing by Braedon Paul

                                                                                                        Written Summary and blog post by Anton Helman, edited by Katie Lin, November, 2025

                                                                                                        Cite this podcast as: Helman, A. Himmel, W. Lin, K. Nondisabling Strokes Recognition and Management. Emergency Medicine Cases. November, 2025. https://emergencymedicinecases.com/nondisabling-strokes-recognition-management. Accessed November 15, 2025

                                                                                                        Résumés EM Cases
                                                                                                        Disabling vs nondisabling strokes

                                                                                                        Nondisabling stroke accounts for a substantial proportion of ED cerebrovascular presentations. Although clinical deficits are mild, the 30-day risk of neurologic deterioration or disabling stroke is about 4-5%. ED priorities include precise phenotyping, urgent vascular imaging when indicated, early secondary prevention, and reliable short-interval follow-up. The key operational pivot is from “major/minor” toward disabling vs nondisabling—a distinction that determines whether to activate reperfusion pathways or pursue prevention-first pathways. Nondisabling stroke is where quiet presentations carry big stakes. Deficits may be subtle, windows feel wider, and the risk of being lulled into false reassurance is real—especially in younger patients and women.

                                                                                                        Pitfall: a common pitfall is getting lulled into a false sense of reassurance for expedited workup when a patient presents with a nondisabling stroke. While nondisabling strokes do not require as rapid workup and treatment as disabling strokes, urgent workup and management should still be a priority.

                                                                                                        As discussed in Part 1, The very first decision is whether the symptoms are disabling vs nondisabling, not whether the presentation is consistent with a “major vs minor” stroke. Disabling means the deficit(s)—if persisted—would compromise independence: language that prevents functional communication, dominant-hand motor weakness that prevents ADLs or work, gait failure, major visual field loss, or depressed consciousness. Nondisabling implies that, even if the deficit remained, independent living would still be possible (e.g., mild facial droop, subtle sensory change, small visual field cut that doesn’t affect reading/driving, mild dysarthria without aphasia). The classification determines tempo: disabling strokes get immediate CT and stroke-protocol CTA to consider reperfusion; nondisabling strokes still demand urgent prevention—non-contrast CT now to screen for intracranial hemorrahge, CTA soon thereafter—but the pathway is focused on stopping the next event.

                                                                                                        Source: Dr. Katie Lin’s SYNAPSE: EM Neuro Essentials Course (www.SynapseCourse.com)

                                                                                                        Stroke miss rate and mimics – the 10% rule 

                                                                                                        Emergency physicians miss approximately 1 in 10 strokes. Short term morbidity and mortality are 8 fold higher in missed strokes. Conversely, a similar proportion of “strokes” turn out to be mimics. Recognizing the difference is critical for avoiding both under- and overtreatment.

                                                                                                        Common stroke mimics
                                                                                                        • Peripheral vestibular disease (vertigo)
                                                                                                        • Metabolic or toxic states (hypo/hyperglycemia, hyponatremia)
                                                                                                        • Seizures and post-ictal paresis (Todd’s paralysis)
                                                                                                        • Atypical migraine
                                                                                                        • Functional neurological disorder (FND)
                                                                                                        • Distinguishing features of stroke vs stroke mimics
                                                                                                          Mimic vs Stroke
                                                                                                          Key Clues
                                                                                                          Onset
                                                                                                          Stroke: abrupt and maximal at onset; Mimic: gradual, spreading (“marching”) symptoms
                                                                                                          Symptom type
                                                                                                          Stroke: negative symptoms (loss of function); Mimic: positive symptoms (tingling, flashes, jerks)
                                                                                                          Distribution
                                                                                                          Stroke: neuroanatomically adjacent (face-arm or arm-leg); Mimic: patchy or shifting
                                                                                                          Laterality
                                                                                                          Stroke: unilateral; Mimic: often bilateral or inconsistent
                                                                                                          Associated signs
                                                                                                          Stroke: objective focal deficits, asymmetric reflexes, pronator drift; Mimic: variable effort, inconsistency, distractibility
                                                                                                          • Check capillary glucose early—hypoglycemia can mimic stroke.
                                                                                                          • Always walk test and check truncal ataxia; missed posterior strokes often result from incomplete cranial nerve and gait testing.
                                                                                                          • Functional Neurologic Disorder (FND) – How to distinguish from stroke

                                                                                                            Functional presentations can mimic stroke. The key is inconsistency and distractibility.

                                                                                                            Bedside Clues for Functional Neurologic Disorder
                                                                                                            • Pronator Drift Test: True central weakness causes pronation + drift; functional weakness often drifts without pronation.
                                                                                                            • Give-way weakness:  Inconsistent effort, especially when resistance is removed at random intervals by the assessor
                                                                                                            • Hoover’s Sign: Lack of contralateral leg extension effort when testing hip flexion.
                                                                                                            • Variable sensory distribution: Inconsistent changes over minutes or shifts sides.
                                                                                                            • Distractibility: Symptoms disappear when attention is diverted.
                                                                                                            • Pitfall: Functional ≠ feigned. Up to 60% of patients with functional presentations have underlying organic disease—always rule out stroke first. Avoid diagnosing a “functional condition” in a patient without prior objective testing and/or neurologic consultation. Err on the side of stroke until proven otherwise. FND features do not exclude stroke.

                                                                                                              Stroke mimic thrombolysis – is it dangerous?

                                                                                                              Data show very low rates of hemorrhage (0–1%) when thrombolytics are given to stroke mimics as compared to the 3–5% seen in true strokes.
                                                                                                              Thus, for disabling presentations, it’s safer to err on the side of treating as a potential true stroke when in doubt, including shared decision-making, informed consent when possible, and timely specialist consultation.

                                                                                                              Why we miss strokes in young people

                                                                                                              Strokes in the young are rare but can be devastating when missed. Approximately 13–18% of all strokes in North America occur in individuals under the age of 50. This proportion has increased over the past two decades. Younger patients are more likely to be labeled migraine, anxiety, or “functional”—particularly women—despite a vascular event. Etiologies also differ: dissection, PFO-related emboli, hypercoagulable states, and intracranial disease figure more prominently, yet we often default to “too young for stroke.”

                                                                                                              • Cognitive traps: “too young,” prior migraine history, normal early CT, “clean” initial CTA.
                                                                                                              • Correctives: keep stroke on the list for patients in their 20s–40s with sudden negative symptoms; do the walk test; order CTA head/neck when the story fits; avoid over-reassurance from normal early imaging if symptoms persist.
                                                                                                              • Etiology awareness: dissection and cardioembolism are a more prominent cause of stroke in younger patients; escalate vascular and cardiac evaluation accordingly.
                                                                                                              • Etiologies of stroke in young adults
                                                                                                                • Cervical artery dissection (carotid or vertebral)
                                                                                                                • Patent foramen ovale (PFO)
                                                                                                                • Sickle cell disease
                                                                                                                • Hypercoagulable states and genetic disorders
                                                                                                                • Atherosclerosis, increasingly seen in 20–40-year-olds
                                                                                                                • Rare causes – including anaphylaxis-induced stroke (histamine-mediated vasospasm similar to Kounis syndrome).
                                                                                                                • Bottom line: Any sudden focal neurological deficit in a young person should be treated as a stroke until proven otherwise.

                                                                                                                  TIA and nondisabling stroke – same urgency, same treatment

                                                                                                                  Non-disabling strokes and TIAs share pathophysiology, prognosis and treatments. The DOUBT study found that 13% of TIA presentations as short as 5 minutes in duration are subsequently found to have evidence of stroke lesions on MRI. 2-17% of patients with TIA or minor stroke suffer a subsequent disabling stroke within 90 days, most within 48 hours.

                                                                                                                  High-risk TIA features: the death of the ABDC2 score

                                                                                                                  The ABCD2 score lacks sufficient sensitivity and specificity to reliably stratify short-term stroke risk after TIA, particularly for identifying patients at very low or very high risk. The score does not account for critical high-risk features such as ipsilateral large artery stenosis, atrial fibrillation, recurrent or crescendo TIAs, or imaging evidence of acute infarction, all of which substantially increase early stroke risk independent of ABCD2 score. As a result, patients with low ABCD2 scores may still harbor significant vascular pathology and face substantial risk, undermining the score’s utility for disposition or management decisions. Instead, current best practice focuses on clinical features to risk stratify patients. These are the features that predict a subsequent disabling stroke and mandate urgent imaging and treatment:

                                                                                                                  • Speech disturbance (aphasia, dysarthria)
                                                                                                                  • Motor weakness
                                                                                                                  • Vision loss
                                                                                                                  • Why persistent deficits in nondisabling stroke and high-risk features in TIA matter

                                                                                                                    Persistent nondisabling deficits and resolved high-risk features share the same message: active cerebrovascular pathology with high risk for early subsequent stroke. A persistent deficit—even when “mild”—raises the pretest probability of a treatable lesion such as symptomatic carotid stenosis, intracranial atherosclerosis, or cervical artery dissection, and the opportunity for secondary prevention. Resolved high-risk features—true motor weakness (often described as heaviness), speech or language disturbance, major visual field loss, or depressed consciousness—suggest potentially high risk vascular territory at risk for susequent stroke from ongoing vascular pathology. Either scenario should trigger urgent head CT to exclude hemorrhage, early CTA head and neck to define the vasculature, and immediate antithrombotic decisions. The goal is to prevent the next stroke event, which is at highest risk within the first 48 hours to one week.

                                                                                                                    Stroke etiology and treatment pathways (Rule of 4s)
                                                                                                                    • ~¼ Large-artery atherosclerosis (carotid/intracranial):

                                                                                                                      • Clues: prior TIA, bruits, focal cortical signs.
                                                                                                                      • Action: CTA head/neck to find carotid stenosis/dissection.
                                                                                                                      • CEA: symptomatic ICA 70–99% stenosis likely to need surgery/stenting; 50–70% often considered for surgery/stenting.
                                                                                                                        • Timing: avoid the first 48 h after stroke; target within ~2 weeks before benefit wanes.
                                                                                                                        • Antithrombotic while waiting for CEA (pre-op): single antiplatelet plus statin and risk-factor control.
                                                                                                                        • ~¼ Lacunar/small-vessel:

                                                                                                                          • Clues: pure motor/sensory syndromes, small deep infarcts.
                                                                                                                          • Action: DAPT and aggressive risk-factor management.
                                                                                                                            • ~¼ Cardioembolic (AF, cardiomyopathy, valve/aortic thrombus, PFO):
                                                                                                                              • Action: ECG/monitoring now; plan oral anticoagulation if indicated when safe (see below) even if imaging looks “lacunar”, may require surgical repair of structural cardiac lesions.
                                                                                                                              • ~¼ Other/cryptogenic (dissection, thrombophilia, hyperviscosity; higher in young):

                                                                                                                                • Clues: neck pain/trauma for dissection; hypercoagulable risk factors; migraine-like prodromes with sudden negative deficits.
                                                                                                                                • ED actions: CTA head/neck to assess dissection/stenosis; short-course (21 days) DAPT for TIA/nondisabling stroke unless cardioembolic mechanism surfaces; coordinate targeted work-up with consultant.
                                                                                                                                • Etiology is not an academic afterthought—it determines secondary prevention timelines, including both medications and interventional procedures. Large-artery atherosclerosis (carotid or intracranial) may require a surgical approach when symptomatic ICA stenosis is present; pre-op therapy is typically single antiplatelet, and the procedural window is early (after the first 48 hours, but ideally within the first couple of weeks). Lacunar or small-vessel disease typically requires an antiplatelet-based prevention strategy with aggressive risk-factor control; thrombolysis is reserved for disabling presentations within the treatment window. Cardioembolic sources (most commonly atrial fibrillation, but also structural heart disease) shift the plan toward oral anticoagulation once it is safe, so an ECG at the time of presentation and arrangements for rhythm monitoring and echocardiography matter even in nondisabling stroke or high risk TIA cases. Cervical artery dissection and other “cryptogenic/other” mechanisms are proportionally more common in younger patients; they necessitate CTA head/neck to confirm the diagnosis and typically lead to a short course of dual antiplatelets for TIA/nondisabling stroke presentations while awaiting confirmatory testing for underlying stroke etiology.

                                                                                                                                  Imaging strategy and timing for nondisabling stroke

                                                                                                                                  The appropriate acute imaging study in suspected ischemic stroke is a stroke-protocol CTA performed immediately, not a delayed “carotid stenosis” CTA intended for elective surgical planning. The stroke-protocol CTA provides time-sensitive information essential to emergency management: identifying the site of occlusion, assessing collateral circulation, and detecting stenosis or dissection that may alter acute therapeutic decisions.

                                                                                                                                  A normal early CT or CTA does not exclude ischemic stroke. Lacunar infarcts, distal vessel occlusions, and small ischemic cores can be radiographically occult in the hyperacute phase. Clinicians should treat the clinical syndrome, and when imaging findings appear discordant with the patient’s presentation, pursue specialist advice rather than prematurely excluding the diagnosis.

                                                                                                                                  Carotid and vertebral Doppler ultrasonography remain useful for secondary prevention and pre-operative assessment, but they do not substitute for CTA when available to inform real-time decisions in the ED.

                                                                                                                                  Carotid endarterectomy (CEA) in nondisabling stroke / high-risk TIA

                                                                                                                                  Carotid endarterectomy remains one of the few surgical interventions in stroke care that meaningfully alters outcomes. Patients with symptomatic internal carotid artery stenosis of 70–99% derive the greatest absolute risk reduction in recurrent stroke with early CEA. Selected patients with 50–69% stenosis may also benefit, depending on plaque/composition/stability, comorbidities, and symptoms.

                                                                                                                                  Timing is critical: CEA is typically deferred for the first 48 hours following ischemic stroke to avoid reperfusion injury in the “hot brain” phase, then performed as soon as safely feasible—ideally within 7–14 days of the index event. The benefit declines substantially with delay beyond two weeks.

                                                                                                                                  Emergency clinician priorities:

                                                                                                                                  • Ensure accurate CTA-based quantification of carotid stenosis.
                                                                                                                                  • Initiate antiplatelet therapy promptly.
                                                                                                                                  • Expedite referral for vascular surgery or stroke specialist evaluation—direct booking of urgent follow-up is often warranted.
                                                                                                                                  • Inititate single-agent antiplatelet therapy promptly (typically aspirin) preoperatively unless dual therapy is specifically recommended by surgical or stroke colleagues.
                                                                                                                                  • Medical therapy  for nondisabling stroke: Secondary prevention

                                                                                                                                    Once intracranial hemorrhage is ruled out:

                                                                                                                                    High-risk TIA and nondisabling stroke live on the same continuum and should be managed with the same urgency. Load antiplatelets in the ED and tailor the regimen to mechanism. Most patients without endarterectomy plans or atrial fibrillation benefit from a short course of dual antiplatelet therapy (DAPT)—typically  21 days—then de-escalation to monotherapy. Pragmatically, aspirin 160–325 mg loading then 81 mg daily combined with clopidogrel 300 mg loading then 75 mg daily is common; aspirin with ticagrelor 180 mg loading then 90 mg twice daily is a reasonable alternative. Benefit is front-loaded in the first three weeks; bleeding risk rises after, which is why DAPT is not continued indefinitely as a standard. Use single antiplatelet therapy if carotid surgery is anticipated, extend dual antiplatelet therapy when intracranial atherosclerosis is the culprit per local protocol, and/or transition to anticoagulation when cardioembolic sources such as atrial fibrillation are identified and it is safe to do so. For symptomatic cervical artery dissection with TIA or nondisabling stroke, treatment typically involves a short course of DAPT, while asymptomatic dissection commonly receives single-agent therapy for months in coordination with the stroke team.

                                                                                                                                    Landmark stroke dual antiplatelet therapy (DAPT) trials
                                                                                                                                    • THALES (2020): Minor ischemic stroke/high-risk TIA—ASA+ticagrelor reduced 30-day stroke or death versus ASA alone; absolute benefit front-loaded with a small increase in major bleeding. Implication: viable DAPT alternative when clopidogrel resistance/genotype is a concern.
                                                                                                                                    • CHANCE-2 (2021): In CYP2C19 loss-of-function carriers, ticagrelor-ASA lowered 90-day stroke versus clopidogrel-ASA without excess severe bleeding. Implication: supports genotype-guided DAPT choice favoring ticagrelor in LOF carriers.
                                                                                                                                    • INSPIRES (2023): Mild stroke/high-risk TIA—clopidogrel-ASA initiated early (often beyond hyper-acute hours) reduced recurrent stroke vs ASA alone; small increase in major bleeding. Implication: reinforces short-course DAPT even with delayed presentation.
                                                                                                                                    • ARAMIS (2023): Minor nondisabling stroke within thrombolysis window—DAPT non-inferior to IV alteplase for 90-day functional outcomes with lower hemorrhagic risk. Implication: in truly nondisabling cases, optimized DAPT may be reasonable when thrombolysis is unlikely to change function.
                                                                                                                                    • Antiplatelet therapy for nondisabling stroke
                                                                                                                                      • Single antiplatelet medication options:

                                                                                                                                        • Aspirin 160–325 mg load → 81 mg daily, or
                                                                                                                                        • Clopidogrel 300 mg load → 75 mg daily (use when ASA allergy/intolerance or DAPT chosen).
                                                                                                                                        • DAPT (short course ~21–28 days):

                                                                                                                                          • ASA + clopidogrel (default in many pathways) then step down to single antiplatelet agent.
                                                                                                                                          • Consider ASA + ticagrelor where clopidogrel resistance/genotype is a concern.
                                                                                                                                          • Avoid DAPT in disabling infarcts (higher bleed risk into established core).
                                                                                                                                          • Etiology-specific nuances:

                                                                                                                                            • Intracranial atherosclerosis: consider DAPT ~90 days.
                                                                                                                                            • Cervical artery dissection: often DAPT ~21 days for TIA/nondisabling stroke; some specialists prefer anticoagulation; asymptomatic dissections frequently single antiplatelet agent ≥6 months.
                                                                                                                                            • Peri-carotid endarectomy: typically single antiplatelet pre-op (confirm with vascular/stroke protocols).
                                                                                                                                            • Anticoagulation after nondisabling stroke – The 1-2-3-4-Day Rule
                                                                                                                                              • Cardioembolic sources (e.g., AF): oral anticoagulation for secondary prevention; initiation/timing individualized (consider infarct size, hemorrhagic risk, and neurology guidance) but typically within 4 days; the trend as of 2025 is to start a DOAC as soon as 24 hrs after the stroke initiation for smaller infarcts with low hemorrhagic transformation risk.

                                                                                                                                              • The “1-2-3-4-Day” rule proposes starting DOACs after ischemic stroke with atrial fibrillation at 1, 2, 3, or 4 days post-event, depending on stroke severity (TIA, mild, moderate, or severe, respectively), and was associated with reduced recurrent stroke or systemic embolism risk without increased major bleeding in both Japanese and European cohorts.
                                                                                                                                              • Blood pressure & lipids after nondisabling stroke
                                                                                                                                                • Avoid aggressive BP reduction in the ED (see Part 1 for details); target gradual control.
                                                                                                                                                • Consider starting high-intensity statin (e.g., atorvastatin 80 mg) unless contraindicated.
                                                                                                                                                • Lifestyle and risk factor management after nondisabling stroke
                                                                                                                                                  • Smoking cessation, diabetes optimization, physical activity, and diet counselling—all should begin in the ED discharge summary or follow-up instructions.

                                                                                                                                                    Disposition decisions for nondisabling stroke

                                                                                                                                                    Disposition decisions for patients presenting with acute nondisabling stroke should be individualized, guided by risk stratification and institutional resources. Admission to a specialized stroke unit is associated with improved outcomes even in nondisabling presentations and should be prioritized when high-risk features are present or reliable outpatient follow-up cannot be assured.

                                                                                                                                                    Admission Criteria for nondisabling stroke

                                                                                                                                                    Hospital admission or observation is recommended for patients with any of the following:

                                                                                                                                                    • Symptomatic extracranial or intracranial stenosis >50%
                                                                                                                                                    • Acute infarction on MRI
                                                                                                                                                    • New-onset atrial fibrillation or other cardioembolic source
                                                                                                                                                    • Recurrent (dual) TIAs or crescendo symptoms
                                                                                                                                                    • Severe or labile hypertension
                                                                                                                                                    • Metabolic derangements or medical instability
                                                                                                                                                    • Uncertain diagnosis or unreliable follow-up
                                                                                                                                                    • Institutional barriers to rapid outpatient evaluation
                                                                                                                                                    • Safe discharge criteria for nondisabling stroke (with follow-up ≤48 hours)

                                                                                                                                                      Selected patients with nondisabling stroke can be discharged safely from the ED when all of the following are satisfied:

                                                                                                                                                      • Mild neurological deficit (NIHSS ≤5)
                                                                                                                                                      • Stable neurological symptoms without recurrence, progression, or fluctuation
                                                                                                                                                      • Brain imaging (CT/MRI) excludes hemorrhage, large vessel occlusion, or high-risk pathology (e.g., >50% carotid stenosis)
                                                                                                                                                      • Lab tests show no significant acute abnormalities (e.g., no atrial fibrillation, troponin elevation, or metabolic derangements)
                                                                                                                                                      • Initiation of secondary prevention: antiplatelet/anticoagulation and statin as indicated
                                                                                                                                                      • Expedited outpatient follow-up arranged within 24-72 hours with stroke or neurology clinic
                                                                                                                                                      • Key take home points for nondisabling stroke recognition and management
                                                                                                                                                        1. Nondisabling strokes account for a substantial proportion of ED cerebrovascular presentations and carry a 4–5% 30-day risk of deterioration or disabling stroke; early recognition, imaging, and secondary prevention remain urgent priorities.
                                                                                                                                                        2. Roughly 1 in 10 strokes are initially missed, and a similar proportion of presumed strokes are mimics (e.g., vestibular disorders, metabolic, migraine, functional neurologic disorder, hypoglycemia). The cost of missing stroke is far greater than treating a mimic. Distinguish by tempo (abrupt vs. gradual), symptom type (negative vs. positive), distribution (neuroanatomic vs. patchy), and laterality (unilateral vs. bilateral). Always rule out hypoglycemia and perform a gait/truncal ataxia assessment to avoid missing posterior strokes.
                                                                                                                                                        3. Features of functional neurologic disorder include inconsistency, give-way weakness, and distractibility. However, functional does not mean feigned—up to 60% have underlying organic disease. Never diagnose “functional stroke” without objective testing and neurology consultation; err on the side of treating as stroke until proven otherwise.
                                                                                                                                                        4. Up to 18% of strokes occur under age 50, often misattributed to migraine, anxiety, or “functional” causes, particularly in women. Maintain suspicion with sudden negative focal deficits and order CTA head/neck when the story fits. Dissection, PFO, and hypercoagulable states are key etiologies.
                                                                                                                                                        5. A common pitfall is underestimating urgency in nondisabling strokes due to subtle deficits, especially in younger patients and women.
                                                                                                                                                        6. TIA and nondisabling stroke share the same pathophysiology, prognosis and treatments—13% of TIAs show infarct on MRI, and up to 17% progress to disabling stroke within 90 days, most within 48 hours. Treat both with equal urgency in imaging and antithrombotic initiation.
                                                                                                                                                        7. Imaging strategies should favor immediate stroke-protocol CTA to identify occlusion, stenosis, or dissection; normal early imaging does not exclude stroke.
                                                                                                                                                        8. Normal early CT/CTA does not necessarily rule out stroke—lacunar and distal lesions may be initially occult. Treat the clinical syndrome and repeat imaging when data conflict with presentation.
                                                                                                                                                        9. Secondary prevention includes initiating antiplatelet therapy, statins, and addressing modifiable risk factors; a 21-day course of dual antiplatelet therapy is common.
                                                                                                                                                        10. Mechanism Dictates Management — The Rule of 4s. Etiology drives therapy:
                                                                                                                                                          • ¼ Large-artery atherosclerosis: DAPT or CEA pathway depending on degree of stenosis, single antiplatelet pre-op.
                                                                                                                                                          • ¼ Lacunar: DAPT, risk-factor control.
                                                                                                                                                          • ¼ Cardioembolic: anticoagulation typically within 4 days, as early as 24hrs.
                                                                                                                                                          • ¼ Other/cryptogenic: dissection, thrombophilia, or hypercoagulable states—often DAPT for 21 days – consult stroke specialist.
                                                                                                                                                          • Carotid endarterectomy timing is vital—ideally within 7–14 days after ischemic stroke in symptomatic carotid stenosis >70% ≤99% and selected patients >50% ≤69%, with deferred surgery in the first 48 hours.
                                                                                                                                                          • Disposition decisions depend on risk stratification; safe discharge requires NIHSS ≤5, stable deficits, no high-risk imaging or lab abnormalities, and guaranteed expedited follow-up.
                                                                                                                                                          • References

                                                                                                                                                             

                                                                                                                                                            The post PODCAST: Nondisabling Stroke Recognition and Management first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                            1 hr 20 min
                                                                                                                                                          • חוסם עורקים PODCAST: Tourniquet Tips
                                                                                                                                                            • Key Points
                                                                                                                                                            • Highlights
                                                                                                                                                            • Introduction

                                                                                                                                                               

                                                                                                                                                              Key Points
                                                                                                                                                              •  Tourniquets save lives and limbs: Apply immediately when you’ve got arterial bleeding.
                                                                                                                                                              •  Placement matters: Position the tourniquet 5–6 cm proximal to the arterial bleed, or if you can’t identify the exact source, place it as high up on the limb as possible.
                                                                                                                                                              •  Windlass technique: The windlass provides only a small amount of extra pressure. Tighten the velcro first, then twist the windlass 1–2 turns to complete compression.
                                                                                                                                                              • Highlights
                                                                                                                                                                • 00:00 Introduction to Tourniquets
                                                                                                                                                                • 00:40 Optimal Placement of Tourniquets
                                                                                                                                                                • 01:21 Proper Tightening Techniques
                                                                                                                                                                • 01:57 Importance of Timing and Application
                                                                                                                                                                • 02:36 Summary and Conclusion
                                                                                                                                                                •  

                                                                                                                                                                  Introduction

                                                                                                                                                                  In this episode of the Rebel Core Content podcast, Swami provides crucial tips on using tourniquets. Highlighting the significance of these life and limb-saving devices, the discussion focuses on the optimal placement of tourniquets, emphasizing placing them 2-3 inches (5-6 cm) above the bleeding source and avoiding joints. Swami also advises on the correct way to tighten the tourniquet using the Velcro strap first, followed by minimal use of the windless. The importance of noting the application time to avoid prolonged arterial flow interruption is also discussed. The episode concludes with a reminder to visit the podcast’s website for more valuable content.

                                                                                                                                                                  The post חוסם עורקים PODCAST: Tourniquet Tips first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                                  4 min
                                                                                                                                                                • PODCAST:Smooth Muscle Relaxator – But does Magnesium Work for Renal Colic?

                                                                                                                                                                  Date: October 10, 2025

                                                                                                                                                                  Guest Skeptic: Dr. Sergey Motov is an Emergency Physician in the Department of Emergency Medicine, Maimonides Medical Center in New York City. He is also one of the world’s leading researchers on pain management in the emergency department. 

                                                                                                                                                                  Case: A 37-year-old man presents to the emergency department (ED) with severe right-sided flank pain.  The pain started about eight hours ago as a vague discomfort in his right flank, but it has gotten progressively worse and now is radiating to his groin. Patient reports nausea, an increased urge to urinate and noticing blood in his urine on one occasion. The patient denies prior medical or surgical history.

                                                                                                                                                                  Upon ED arrival, his vital signs are normal. Physical examination revealed a stated age patient in distress due to severe right flank pain, prominent right-sided costovertebral angle tenderness, and absence of abdominal tenderness or guarding. While strongly considering renal colic in differential diagnosis and reaching for the bedside ultrasound, you are wondering if a single dose of a non-steroidal anti-inflammatory (NSAID) will be enough to relieve this patient’s pain, or should you add Magnesium or Lidocaine?

                                                                                                                                                                  Background: Renal colic is a common and extremely painful emergency department (ED) complaint encountered in the ED that frequently recurs. The nonsteroidal anti-inflammatory drugs (NSAIDs) given intravenously or intramuscularly (IM) are frequently used as first-line therapy. However, about 30% of ED patients receiving NSAIDS require rescue analgesia in the form of opioids. Opioid use, though effective, is limited at times due to the potentially dangerous adverse effects. Thus, there might be a role for other non-opioid classes of drugs to be co-administered with NSAIDs for relief of renal colic.

                                                                                                                                                                  Magnesium sulfate (MgSO₄) has been suggested as a possible treatment option. It may blunt ureteral smooth muscle spasm by antagonizing calcium influx in smooth muscle and by N‑methyl‑D‑aspartate (NMDA) receptor antagonism. These are mechanisms that can reduce visceral pain and augment other analgesics. Small ED trials and meta‑analyses suggest MgSO₄ can reduce pain scores and opioid use in renal colic, though the evidence base has been limited and heterogeneous [1].

                                                                                                                                                                  Another suggested treatment modality for renal colic is intravenous lidocaine. We looked at this treatment on SGEM#202 and were unimpressed with the efficacy. Systemic lidocaine blocks voltage‑gated sodium channels and appears to modulate central sensitization and visceral pain pathways. In ED populations, systematic reviews indicate IV lidocaine offers variable analgesia with a mixed signal for benefit, and renal colic–specific RCTs suggest it may be inferior to ketorolac and best considered (if at all) as part of a multimodal strategy rather than as monotherapy [2].

                                                                                                                                                                  Clinical Question: In adult ED patients with suspected renal colic receiving IM diclofenac, does adding IV magnesium sulfate or IV lidocaine increase the proportion achieving ≥50% reduction in pain at 30 minutes compared to a saline placebo?

                                                                                                                                                                  Reference: Toumia M, Sassi S, Dhaoui R, et al. Magnesium Sulfate Versus Lidocaine as an Adjunct for Renal Colic in the Emergency Department: A Randomized, Double-Blind Controlled Trial. Ann Emerg Med 2024

                                                                                                                                                                  • Population: The study enrolled adults aged 18 to 65 years with suspected acute renal colic and a pain score of 5 or more on a 10-point numerical rating scale (NRS).
                                                                                                                                                                    • Exclusions: Pregnancy/breastfeeding; NSAID, MgSO₄, or lidocaine contraindication or allergy; renal/hepatic dysfunction; analgesic use in prior 6 h; bleeding diathesis or GI hemorrhage; significant CAD/arrhythmia; seizures; peritoneal signs; altered mental status; anticoagulation; hemodynamic instability; morphine allergy.
                                                                                                                                                                    • Intervention: All patients received 75 mg IM diclofenac. The intervention groups then received either 1g IV MgSO₄ (10 mL) over 2-4 minutes or 1.5 mg/kg IV lidocaine (10 mL) over 2-4 minutes.
                                                                                                                                                                    • Comparison: Placebo(10 mL normal saline) after 75 mg IM diclofenac.
                                                                                                                                                                    • Outcome:
                                                                                                                                                                      • Primary Outcome: The proportion of participants achieving at least a 50% reduction in the NRS score at 30 minutes after drug administration.
                                                                                                                                                                      • Secondary Outcomes: Need for rescue analgesia, time required for 50% pain reduction, proportion of participants with persistent pain (NRS>2) at 90 minutes, frequency of adverse events, and frequency of return visits to the ED for renal colic recurrence.
                                                                                                                                                                      • Type of Study: Prospective, multicenter, randomized, double‑blind, placebo‑controlled, 3-arm trial conducted from November 2022 to August 2023 in three academic hospital EDs and one regional hospital ED in Tunisia.
                                                                                                                                                                      • Authors’ Conclusions: “Adding intravenous MgSO4, but not lidocaine, to IM diclofenac offered superior pain relief but at levels below accepted thresholds for clinical importance.” 

                                                                                                                                                                        Quality Checklist for Randomized Clinical Trials:

                                                                                                                                                                        1. The study population included or focused on those in the emergency department. Yes
                                                                                                                                                                        2. The patients were adequately randomized. Yes
                                                                                                                                                                        3. The randomization process was concealed. Yes
                                                                                                                                                                        4. The patients were analyzed in the groups to which they were randomized. Yes
                                                                                                                                                                        5. The study patients were recruited consecutively (i.e. no selection bias). Unsure
                                                                                                                                                                        6. The patients in both groups were similar with respect to prognostic factors. Yes
                                                                                                                                                                        7. All participants (patients, clinicians, outcome assessors) were unaware of group allocation. Yes
                                                                                                                                                                        8. All groups were treated equally except for the intervention. Yes
                                                                                                                                                                        9. Follow-up was complete (i.e. at least 80% for both groups). Yes
                                                                                                                                                                        10. All patient-important outcomes were considered. Yes
                                                                                                                                                                        11. The treatment effect was large enough and precise enough to be clinically significant. No
                                                                                                                                                                        12. Financial conflicts of interest. This study was conducted without financial support. The authors have no conflict of interest relevant to this article to disclose.
                                                                                                                                                                        13. Results: They screened 1,321 patients and included 840 who were randomized (280 per arm). The mean age is in the mid 40s with a fairly even male/female split. The mean baseline NRS ~8.5–8.7. Ultrasound showed stones in ~20% and pyelocaliceal dilation in over one-third of patients.

                                                                                                                                                                          Key Result: Adding IV MgSO₄ to IM diclofenac increased the proportion of patients achieving ≥50% pain reduction at 30 min and reduced rescue analgesia use, but pain score differences never reached the 1.3‑point MCID, while IV lidocaine was not superior to diclofenac alone.
                                                                                                                                                                          • Primary Outcome: ≥50% NRS reduction at 30 minutes
                                                                                                                                                                            • MgSO₄ + diclofenac: 227/280 (81.7%)
                                                                                                                                                                            • Lidocaine + diclofenac: 204/280 (72.9%)
                                                                                                                                                                            • Placebo + diclofenac: 201/280 (71.8%)
                                                                                                                                                                              • MgSO₄ vs lidocaine +8.8% (95% CI 1.89–15.7, p=0.013)
                                                                                                                                                                              • MgSO₄ vs control +9.9% (95% CI 2.95–16.84, p=0.004).
                                                                                                                                                                                • Secondary Outcomes:
                                                                                                                                                                                  • Rescue analgesia: Lower need in MgSO₄ group (17.1%) versus lidocaine (22.5%) and control (28.9%).
                                                                                                                                                                                  • Time to 50% pain reduction: No significant differences between groups (approximately 21 minutes for all groups).
                                                                                                                                                                                  • Persistent pain at 90 minutes: Similar across groups (20-22.1% with NRS>2).
                                                                                                                                                                                  • Return ED visits: No differences (22-26%)
                                                                                                                                                                                  • Adverse events: Significantly more in MgSO₄ group (57.1%) versus control (22.5%), primarily facial flushing (48% MgSO₄ vs 10% Lido vs 14% placebo)
                                                                                                                                                                                    1. Statistical vs. Clinical Significance: This study exemplifies a critical issue in clinical research: achieving statistical significance without clinical importance. While the primary outcome showed statistical significance for MgSO₄ lidocaine and even more so for control, the actual NRS differences were all below 0.5 points at every time point. In addition, no between-group differences reached the generally accepted reduction of 1.3 for being clinically important [3,4]. There are concerns in the literature about what is considered a minimally important difference (MID) or minimally clinically important difference (MCID) [5, 6].
                                                                                                                                                                                    2. Choice of Primary Outcome Metric: The primary outcome was the proportion of patients achieving ≥50% pain reduction rather than the actual change in pain scores. This dichotomization of a continuous variable has several problems:
                                                                                                                                                                                      • Loss of Information: Converting continuous NRS data to a binary outcome discards valuable information about the magnitude of pain relief. For example, a patient going from NRS 10 to 5 (50% reduction) is counted the same as a patient going from 10 to 2 (80% reduction), yet these represent vastly different clinical scenarios.
                                                                                                                                                                                      • Arbitrary Threshold: The 50% reduction threshold, while commonly used, may not represent meaningful relief for all patients. For example, some patients with NRS 10→5 may still require rescue analgesia, while others with NRS 10→6 (40% reduction) might be satisfied.
                                                                                                                                                                                      • Diagnostic Verification of Kidney Stone: The diagnosis of renal colic was based on emergency physician clinical judgment or imaging with ultrasound showing direct or indirect signs of urinary tract stones in only 58% of participants when performed. This is consistent with current radiology, emergency medicine and urology guidelines not to get imaging on all patients [7].  We cover this on the SGEM Xtra: Come Together, Right Now…Over Renal Colic. While this approach may increase real-world applicability (generalizability), the “suspected renal colic” inclusion without universal confirmatory imaging may reduce internal validity and introduce misclassification bias. A confirmed stone sensitivity analysis would have helped strengthen the findings.
                                                                                                                                                                                      • Adjunct to IM Rather Than IV NSAID: While acknowledging and respecting the authors’ standard of care practice of using IM Diclofenac, there are several important implications:
                                                                                                                                                                                        • Delayed NSAID Absorption: IM administration results in slower and more variable absorption compared to IV administration. Peak plasma concentrations occur at 20-60 minutes with IM NSAIDs versus 5-10 minutes with IV administration. This delay may have limited the synergistic potential of the IV adjuncts.
                                                                                                                                                                                        • Limited generalizability: The authors stated that IM diclofenac is “most frequently administered in our emergency setting,” which may reflect local practice but limits generalizability to settings using IV NSAIDs more globally, with IV ketorolac being the most used NSAID.
                                                                                                                                                                                        • Timing of Effect: The NRS measurements at 5, 10, and 20 minutes may primarily reflect the IV medication effects, while the 30 to 90-minute assessments may include increasing contribution from the IM diclofenac. This could confound the interpretation of the adjunct effects.
                                                                                                                                                                                        • Multiple Injections: Patients received both an IM injection and IV access/infusion, increasing procedural burden (and unnecessary pain) compared to a single IV administration strategy
                                                                                                                                                                                        • Unmasking: Both agents were given as single boluses over 2-4 minutes rather than short infusion (a common practice in North America when used for pain) that might have been responsible for much higher rates of “minor” adverse effects (facial flushing and vomiting) in the Magnesium Group, and dizziness in the Lidocaine group. These adverse events may have unmasked the patient and clinicians to group allocation. To investigate this potential bias, it would have been helpful to survey the participants and clinicians as to which group they thought the patient had been randomized to.
                                                                                                                                                                                        • Comment on Authors’ Conclusion Compared to SGEM Conclusion: We would have tweaked the conclusion to say: Adding intravenous MgSO₄, but not lidocaine, to IM diclofenac MAY offer superior pain relief, but at levels below accepted thresholds for clinical importance.

                                                                                                                                                                                          SGEM Bottom Line: While MgSO₄ when added to IM NSAIDs for renal colic, may provide a statistically superior pain relief to Lidocaine and Placebo, and less rescue opioid use, the magnitude of benefit is small, has questionable clinical relevance and comes with an increased rate of adverse effects.

                                                                                                                                                                                          Case Resolution: You proceeded with administration of 10mg of IV Ketorolac as a single agent, and upon assessment of the patient at 20 minutes, the patient verbalized significant pain relief without experiencing any adverse effects. Urinalysis is positive for blood, while complete blood count, complete metabolic panel, and the remainder of the urinalysis are normal.  A non-contrast CT scan reveals a 4 mm non-obstructing stone in the right distal ureter.

                                                                                                                                                                                          Dr. Sergey Motov

                                                                                                                                                                                          Clinical Application: Intravenous adjunctive MgSO₄ does not seem to provide clinically meaningful pain relief in patients with renal colic but leads to frequent development of facial flashing. This precludes if from routine use in the ED for patients with renal colic. Similarly, IV lidocaine combined with parenteral NSAIDs does not provide clinically meaningful pain relief in patients with renal colic, and the evidence doesn’t support its use at this time.

                                                                                                                                                                                          What Do I Tell the Patient?  It looks like you have classic kidney‑stone pain. I will order an IV analgesic called ketorolac that should reduce your pain and make you more comfortable. However, if you are still in pain in 15-20 minutes after receiving this medication, I will proceed with ordering intravenous morphine.

                                                                                                                                                                                          Keener Kontest: Last week’s winner was Dr. Steven Steltz from NZ. He knew it was called Cable Beach in Broome, Western Australia, because it was the site where an undersea telegraph cable came ashore in 1889, connecting Australia to the rest of the world via Java.

                                                                                                                                                                                          Listen to the SGEM podcast this week to hear the trivia question. If you know the answer, send an email to [email protected] with “keener” in the subject line. The first correct answer will receive a cool skeptical prize.

                                                                                                                                                                                          Other SGEM Episodes:

                                                                                                                                                                                          • SGEM#4: Getting Un-Stoned (Renal Colic and Alpha Blockers)
                                                                                                                                                                                          • SGEM#32: Stone Me (Fluids and Diuretics for Renal Colic)
                                                                                                                                                                                          • SGEM #71: Like a Rolling Kidney Stone (A Systematic Review of Renal Colic)
                                                                                                                                                                                          • SGEM#154: Here I Go Again, Kidney Stone
                                                                                                                                                                                          • SGEM#202: Lidocaine for Renal Colic?
                                                                                                                                                                                          • SGEM#220: Acupuncture vs. Morphine for Renal Colic
                                                                                                                                                                                          • SGEM#230: Tamsulosin – You’ve Lost that Loving Feeling – For Renal Colic
                                                                                                                                                                                          • SGEM#389: Does Dex, Dex, Dex, Dexamethasone Help with Renal Colic?
                                                                                                                                                                                          • Remember to be skeptical of anything you learn, even if you heard it on the Skeptics’ Guide to Emergency Medicine.

                                                                                                                                                                                            References: 

                                                                                                                                                                                            1. Jokar A, Cyrus A, Babaei M, Taheri M, Almasi-Hashiani A, Behzadinia E, Yazdanbakhsh A. The Effect of Magnesium Sulfate on Renal Colic Pain Relief; a Randomized Clinical Trial. Emerg (Tehran). 2017;5(1):e25. Epub 2017 Jan 10. PMID: 28286832; PMCID: PMC5325894.
                                                                                                                                                                                            2. Zhong J, Hu J, Mao L, Ye G, Qiu K, Zhao Y, Hu S. Efficacy of Intravenous Lidocaine for Pain Relief in the Emergency Department: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2022 Jan 17;8:706844. doi: 10.3389/fmed.2021.706844. PMID: 35111766; PMCID: PMC8801430.
                                                                                                                                                                                            3. Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med. 2003 Apr;10(4):390-2. doi: 10.1111/j.1553-2712.2003.tb01355.x. PMID: 12670856.
                                                                                                                                                                                            4. Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017 Feb 20;15(1):35. doi: 10.1186/s12916-016-0775-3. PMID: 28215182; PMCID: PMC5317055.
                                                                                                                                                                                            5. Tsujimoto Y, Fujii T, Tsutsumi Y, Kataoka Y, Tajika A, Okada Y, Carrasco-Labra A, Devji T, Wang Y, Guyatt GH, Furukawa TA. Minimal important changes in standard deviation units are highly variable and no universally applicable value can be determined. J Clin Epidemiol. 2022 May;145:92-100. doi: 10.1016/j.jclinepi.2022.01.017. Epub 2022 Jan 25. PMID: 35091045.
                                                                                                                                                                                            6. Carrasco-Labra A, Devji T, Qasim A, Phillips MR, Wang Y, Johnston BC, Devasenapathy N, Zeraatkar D, Bhatt M, Jin X, Brignardello-Petersen R, Urquhart O, Foroutan F, Schandelmaier S, Pardo-Hernandez H, Hao Q, Wong V, Ye Z, Yao L, Vernooij RWM, Huang H, Zeng L, Rizwan Y, Siemieniuk R, Lytvyn L, Patrick DL, Ebrahim S, Furukawa TA, Nesrallah G, Schünemann HJ, Bhandari M, Thabane L, Guyatt GH. Minimal important difference estimates for patient-reported outcomes: A systematic survey. J Clin Epidemiol. 2021 May;133:61-71. doi: 10.1016/j.jclinepi.2020.11.024. Epub 2020 Dec 13. PMID: 33321175.
                                                                                                                                                                                            7. Moore CL, Carpenter CR, Heilbrun ML, Klauer K, Krambeck AC, Moreno C, Remer EM, Scales C, Shaw MM, Sternberg KM. Imaging in Suspected Renal Colic: Systematic Review of the Literature and Multispecialty Consensus. J Urol. 2019 Sep;202(3):475-483. doi: 10.1097/JU.0000000000000342. Epub 2019 Aug 8. PMID: 31412438.
                                                                                                                                                                                            8. The post PODCAST:Smooth Muscle Relaxator – But does Magnesium Work for Renal Colic? first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                                                              46 min
                                                                                                                                                                                            9. PODCAST: The Warrior – Pharmacological Interventions for the Acute Treatment of Hyperkalemia

                                                                                                                                                                                              Reference: Jessen et al. Pharmacological interventions for the acute treatment of hyperkalaemia: A systematic review and meta-analysis. Resuscitation 2025

                                                                                                                                                                                              Date: August 6, 2025

                                                                                                                                                                                              Guest Skeptic: William Toon is a paramedic who, this past May achieved over 50 years of continuous EMS certification. His professional path has taken him from front-line paramedic to national presenter, expert witness, flight medic, EMS program director, and senior training executive with a doctorate in Higher Education.

                                                                                                                                                                                              Case: A 65-year-old patient presents to the emergency department (ED) with general weakness, mild abdominal cramping, and nausea over the past 12 hours. The patient has poorly controlled type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease stage 4 on hemodialysis. The patient missed their last dialysis appointment two days ago. The patient takes several medications for kidney disease and blood pressure, including a potassium-sparing diuretic. His ECG shows peaked T-waves. Stat chemistry reveals a serum potassium of 6.5 mmol/L. He is not yet oliguric and is hemodynamically stable. The team must initiate pharmacologic treatment immediately while preparing for possible escalation to dialysis.

                                                                                                                                                                                              Background: Hyperkalemia is a potentially life-threatening electrolyte abnormality frequently encountered in the ED. It’s common in patients with chronic kidney disease, diabetes, or those on renin-angiotensin-aldosterone system (RAAS) inhibitors. While treatments like insulin, beta-agonists, and calcium gluconate are well-known, the comparative efficacy and safety of pharmacologic agents used to rapidly reduce serum potassium remain uncertain.

                                                                                                                                                                                              Clinicians must balance rapid action with safety when choosing treatment for hyperkalemia. Understanding which pharmacologic interventions work best and how quickly they act is vital to optimizing care. Unfortunately, much of the existing data on hyperkalemia treatment is derived from small or methodologically limited trials.

                                                                                                                                                                                              Clinical Question: What is the effectiveness of pharmacological interventions in the acute treatment of hyperkalemia compared to standard care, placebo, or other interventions in adults?

                                                                                                                                                                                              Reference: Jessen et al. Pharmacological interventions for the acute treatment of hyperkalaemia: A systematic review and meta-analysis. Resuscitation 2025

                                                                                                                                                                                              • Population: Adult patients with hyperkalemia (typically defined as serum potassium ≥5.0 mmol/L). Studies included varied populations such as those with CKD, dialysis patients, and acutely ill inpatients.
                                                                                                                                                                                                • Exclusions: Patients under 18 and those receiving non-pharmacologic interventions (dialysis) were excluded.
                                                                                                                                                                                                • Intervention: Any acute pharmacological intervention to mitigate the harmful effects of hyperkalemia or to lower potassium levels.
                                                                                                                                                                                                • Comparison: Placebo, standard care, or head-to-head comparisons of other pharmacologic interventions.
                                                                                                                                                                                                • Outcome:
                                                                                                                                                                                                  • Primary Outcome: Change in serum potassium from baseline at specific time points (1, 2, 4, and 6 hours).
                                                                                                                                                                                                  • Secondary Outcomes: Proportion of patients achieving normokalaemia, adverse events (hypoglycaemia), need for rescue therapy (dialysis), and all-cause mortality.
                                                                                                                                                                                                  • Type of study: Systematic review and meta-analysis
                                                                                                                                                                                                  • Authors’ Conclusions: “Evidence supports treatment with insulin in combination with glucose, inhaled or intravenous salbutamol, or the combination. No evidence supporting a clinical effect of calcium or bicarbonate for hyperkalaemia was identified.”

                                                                                                                                                                                                    Quality Checklist for Therapeutic Systematic Reviews:

                                                                                                                                                                                                    1. The clinical question is sensible and answerable. Yes
                                                                                                                                                                                                    2. The search for studies was detailed and exhaustive. Yes
                                                                                                                                                                                                    3. The primary studies were of high methodological quality. No
                                                                                                                                                                                                    4. The assessment of studies were reproducible. Yes
                                                                                                                                                                                                    5. The outcomes were clinically relevant. Yes
                                                                                                                                                                                                    6. There was low statistical heterogeneity for the primary outcomes. No
                                                                                                                                                                                                    7. The treatment effect was large enough and precise enough to be clinically significant. Yes
                                                                                                                                                                                                    8. Who funded the trial? No financial support was provided for the study.
                                                                                                                                                                                                    9. Did the authors declare any conflicts of interest? No relevant conflicts of interest disclosed.
                                                                                                                                                                                                    10. Results: Studies included adult patients with hyperkalemia from EDs, inpatient wards, and dialysis units. Ages ranged widely, with a predominance of patients with chronic kidney disease (CKD) and cardiovascular comorbidities.

                                                                                                                                                                                                      Key Result: Sodium zirconium cyclosilicate and insulin-glucose regimens were most effective in lowering serum potassium within four hours, while other agents had limited short-term impact.
                                                                                                                                                                                                      • Primary Outcome: At four hours, insulin-glucose reduced potassium by an average of 0.8 mmol/L, and sodium zirconium cyclosilicate by 0.67 mmol/L. SPS (sodium polystyrene sulfonate) and patiromer showed smaller and delayed effects.
                                                                                                                                                                                                      • Secondary Outcomes: Hypoglycemia occurred in 17% of insulin-treated patients. Dialysis was needed in 6.2%. Mortality rates were not significantly different among treatment groups.
                                                                                                                                                                                                        1. Substantial Clinical and Methodological Heterogeneity: One of the most important limitations of this SRMA was the considerable heterogeneity in study design, patient populations, baseline potassium levels, and definitions of hyperkalemia. For example, some studies included only CKD patients, while others focused on acutely ill hospitalized individuals or dialysis-dependent populations. Furthermore, the timing of outcome measurements varied, making direct comparisons difficult. This heterogeneity undermines the consistency of pooled estimates and limits the applicability of the findings to specific ED populations.
                                                                                                                                                                                                        2. Risk of Bias in Primary Studies: Many of the included trials had methodological weaknesses, including poor allocation concealment, lack of masking, and incomplete outcome data. Several studies did not clearly describe their randomization procedures. These issues increase the risk of performance and detection bias, especially when subjective outcomes or clinician decisions like the need for dialysis. The GRADE framework used by the authors appropriately rated much of the evidence as “low” or “very low” certainty for key comparisons. These biases raise doubts about the internal validity of the SRMA conclusions and highlight the need for better-quality trials in this domain.
                                                                                                                                                                                                        3. Co-Interventions and Protocol Variability: A recurring issue was the use of multiple simultaneous treatments across arms, such as combining insulin, beta-agonists, and calcium gluconate in varying doses and sequences. This practice, while clinically realistic and pragmatic, muddled the attribution of treatment effect to any single agent. In real-world ED settings, polytherapy is common, but in research, this confounds the estimation of the independent effectiveness of each drug. Without stratified analyses that control for such co-interventions, it is difficult to know whether observed reductions in potassium were due to one agent or the combination of agents. This limits the SRMA’s ability to inform what might be the best therapeutic option.
                                                                                                                                                                                                        4. Sample Sizes and Few Events: Despite including over 100 studies, many of the comparisons within the SRMA were based on small individual trials with limited numbers of participants and few outcome events. As an example, data on adverse effects like hypoglycemia or need for dialysis were inconsistently reported and often underpowered to detect differences. The lack of data leads to wide confidence intervals and imprecise point estimates, which weaken the clinical significance and reproducibility of the findings.
                                                                                                                                                                                                        5. Lack of Focus on ED-Specific Contexts: Though the SRMA is highly relevant to emergency medicine, only a minority of included studies were conducted in ED settings. Many trials were hospital-based or conducted in specialized units like nephrology wards, and some included stable outpatient populations. This matters because ED patients often present with more acute symptoms, comorbidities, and a need for rapid intervention. Additionally, drug availability and workflow constraints in the ED differ from other settings. Therefore, the external validity of the findings to ED practice is limited, and the SRMA may not fully capture the nuances of time-sensitive decision-making in the ED environment.
                                                                                                                                                                                                        6. Comment on Authors’ Conclusion Compared to SGEM Conclusion: We agree with the authors’ conclusions but would emphasize the limited certainty and highlight the need for better patient-oriented outcome data before changing practice broadly. 

                                                                                                                                                                                                          SGEM Bottom Line: Insulin-glucose remains a reliable first-line agent for acute hyperkalemia management, but newer agents like sodium zirconium cyclosilicate show promise and may play a complementary role.

                                                                                                                                                                                                          Case Resolution: You administer 10 units of IV insulin with an amp of D50 and initiate inhaled albuterol. You consult nephrology and start sodium zirconium cyclosilicate, which is available in your ED. Repeat potassium at four hours drops to 5.4 mmol/L. No dialysis is needed.

                                                                                                                                                                                                          William Toon

                                                                                                                                                                                                          Clinical Application: This SRMA reaffirms insulin-glucose as the first-line treatment for hyperkalemia in the ED. It also supports adding beta-agonists when needed, de-emphasizing bicarbonate and sodium polystyrene sulfonate in acute settings, and suggests newer agents like SZC for future integration into your ED’s hyperkalemia protocol.

                                                                                                                                                                                                          However, it does not mean we should not use calcium gluconate or chloride in patients with hyperkalemia. These agents are not meant to lower potassium levels, and it would be inappropriate to have expected them to do so. The SRMA did not demonstrate a patient-oriented outcome (POO) of benefits. We should interpret the findings cautiously. The absence of evidence of benefit is not the same as evidence of no benefit. Therefore, calcium should not be abandoned for the acute treatment of hyperkalemia solely based on this SRMA.

                                                                                                                                                                                                          What Do I Tell the Patient? We’re treating your high potassium levels quickly to protect your heart. We’ve given insulin and another medicine to bring the levels down safely. We’ll keep monitoring you closely over the next few hours.

                                                                                                                                                                                                          Keener Kontest: Last week’s winner was David Michaelson. He knew that TENS units are thought to reduce pain through the gate control mechanism and the release of endorphins.

                                                                                                                                                                                                          Listen to the SGEM podcast for this week’s question. If you know, then send an email to [email protected] with “keener” in the subject line. The first correct answer will receive a shoutout on the next episode.

                                                                                                                                                                                                          The post PODCAST: The Warrior – Pharmacological Interventions for the Acute Treatment of Hyperkalemia first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                                                                          23 min
                                                                                                                                                                                                        7. PODCAST: The Limping Child

                                                                                                                                                                                                          Limping is a common complaint in pediatric emergency care, but the differential is broad and the stakes are high. In this episode, we walk through a detailed, age-based approach to the evaluation of the limping child. You’ll learn how to integrate the Kocher criteria, when imaging and labs are truly necessary, and how to avoid being misled by small joint effusions on ultrasound. We also highlight critical mimics like appendicitis, testicular torsion, and malignancy—and remind you why watching a child walk is one of the most valuable parts of the exam. Whether it’s transient synovitis, septic arthritis, or something much more concerning, this episode gives you the tools to manage pediatric limps with confidence.

                                                                                                                                                                                                          Learning Objectives
                                                                                                                                                                                                          1. Apply an age-based approach to the differential diagnosis of limping in children.
                                                                                                                                                                                                          2. Demonstrate diagnostic reasoning by integrating history, physical exam, imaging, and lab findings to prioritize urgent conditions like septic arthritis and SCFE.
                                                                                                                                                                                                          3. Appropriately select and interpret imaging and lab studies, including understanding the utility and limitations of ultrasound, MRI, and the Kocher criteria.
                                                                                                                                                                                                          4. Connect with Brad Sobolewski

                                                                                                                                                                                                            Mastodon: @[email protected]

                                                                                                                                                                                                            PEMBlog: PEMBlog.com

                                                                                                                                                                                                            Blue Sky: @bradsobo

                                                                                                                                                                                                            X (Twitter): @PEMTweets

                                                                                                                                                                                                            Instagram: Brad Sobolewski

                                                                                                                                                                                                            The post PODCAST: The Limping Child first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                                                                            13 min
                                                                                                                                                                                                          5. EM Pharmacotherapy Literature of 2024
                                                                                                                                                                                                            EM Pharmacotherapy Literature of 2024
                                                                                                                                                                                                            August 28, 2025

                                                                                                                                                                                                            Written by Amanda Mathews


                                                                                                                                                                                                            This article reviewed major ED pharmacotherapy studies from 2024, including topics such as anticoagulation reversal, seizure prophylaxis in TBI, and thrombolysis in ischemic stroke.

                                                                                                                                                                                                            Update your pharmacopia 

                                                                                                                                                                                                            There are a lot of great studies highlighted in this article. Here are a few big takeaways.

                                                                                                                                                                                                            • Resuscitation
                                                                                                                                                                                                              • ACC (American College of Cardiology) clinical recommendation for ED treatment of acute heart failure is initial IV dosing of 1-2.5x home oral-dose furosemide, with 2.5x dosing associated with greater fluid loss, increased weight loss, and decreased dyspnea at 72 hours.
                                                                                                                                                                                                                • An international multispecialty task force looked at corticosteroid use in sepsis, ARDS, and community-acquired pneumonia (CAP). Corticosteroids are suggested for use in adults hospitalized in ARDS and recommended for adults hospitalized in severe CAP.
                                                                                                                                                                                                                • Trauma
                                                                                                                                                                                                                  • Updated guidelines for antibiotic prophylaxis in trauma. See Table at the bottom of this summary.
                                                                                                                                                                                                                  • TBI/ICH
                                                                                                                                                                                                                    • Clinical practice guideline showed no evidence of benefit or harm regarding prophylactic anti-seizure medication in moderate to severe TBI. If used, guidelines recommend leviteracetam.
                                                                                                                                                                                                                      • Two studies looked at TXA use in TBI. One meta-analysis did not show any mortality benefit or overall improvement in clinical outcome, but there was a decrease in hematoma expansion and hemorrhagic volume. The other study looked at TXA dosing and found that, if you do give TXA, a 2g IV initial dosing strategy is associated with better six-month disability scores.
                                                                                                                                                                                                                      • Anticoagulation reversal
                                                                                                                                                                                                                        • Two studies looked at adexanet alfa for reversal of Factor Xa inhibitor associated bleeding. Neither study showed improved functional outcomes in patients who received adexanet alfa compared to prothrombin complex concentrate (PCC).
                                                                                                                                                                                                                          • Researchers compared fixed-dose with weight-based dosing for PCC reversal of vitamin K antagonist bleeding. Fixed dose was effective in achieving INR <2.0 and had fewer adverse effects compared to weight based dosing; however, weight based was better at tighter INR control of <1.5.
                                                                                                                                                                                                                          • Ischemic stroke
                                                                                                                                                                                                                            • Multiple studies looked at tenecteplase (TNK) vs. alteplase for use in ischemic stroke. Ultimately, these studies showed TNK dosed at 0.25 mg/kg (max 25mg) was noninferior to alteplase 0.9 mg/kg (max 90mg) when used in acute ischemic stroke within 4.5 hours of symptom onset.
                                                                                                                                                                                                                            • Severe agitation
                                                                                                                                                                                                                              • ACEP subcommittee published a clinical policy on medication for the treatment of severe agitation. The committee favored the combination of droperidol and midazolam if possible, and droperidol if only a single drug can be used. If droperidol is unavailable, they recommended an atypical anti-psychotic.
                                                                                                                                                                                                                              • How does this change my practice?

                                                                                                                                                                                                                                This is a really great summary article that is a must-read for any practicing ED physician. Many of these subjects have been covered on Journal Feed in the last year, and there will continue to be more studies published on these topics moving forward. I enjoyed this review on important topics like IV thrombolysis and AC reversal.

                                                                                                                                                                                                                                Source

                                                                                                                                                                                                                                CuratED: The emergency medicine pharmacotherapy literature of 2024. Am J Emerg Med. 2025 Jul;93:146-153. doi: 10.1016/j.ajem.2025.03.046. Epub 2025 Mar 24. PMID: 40203497

                                                                                                                                                                                                                                The post EM Pharmacotherapy Literature of 2024 first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                                                                                                4 min
                                                                                                                                                                                                                              • PODCAST: Airway Management in TBI or Ischemia
                                                                                                                                                                                                                                ​

                                                                                                                                                                                                                                Try Alex (chatbot in right lower corner of the website)

                                                                                                                                                                                                                                Evidence-based, fully-referenced answers

                                                                                                                                                                                                                                ​Airway Management in TBI or Ischemia​

                                                                                                                                                                                                                                Published on September 1, 2025

                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                Written by Vivian Lei


                                                                                                                                                                                                                                This is a concise, evidence-based approach to intubating patients with acute brain injury while minimizing secondary brain injury and preserving cerebral perfusion.

                                                                                                                                                                                                                                Mindful Intubation

                                                                                                                                                                                                                                Emergency airway management in patients with acute brain injury or ischemia poses unique challenges, with a risk of causing secondary brain injury. Here’s how to optimize outcomes in this high-risk population.

                                                                                                                                                                                                                                • Primary goal- Prevent secondary brain injury from hypoxia, hypotension, hyper/hypocarbia, or increased intracranial pressure (ICP).
                                                                                                                                                                                                                                  • Before intubation-
                                                                                                                                                                                                                                    • Perform a rapid but thorough neurological exam (GCS, pupils, motor function, speech).
                                                                                                                                                                                                                                    • Optimize oxygenation with preoxygenation (NRB, HFNC, NIPPV, or BVM) and apneic oxygenation.
                                                                                                                                                                                                                                    • Avoid hypotension. Maintain MAP 80–100 mmHg. Individualize based on the patient’s baseline BP.
                                                                                                                                                                                                                                    • Address suspected ICP elevation while preserving cerebral perfusion pressure (CPP). Elevate head of bed 30°, avoid jugular compression, ensure proper cervical collar fit.
                                                                                                                                                                                                                                      • During intubation-
                                                                                                                                                                                                                                        • Consider fentanyl (2–3 mcg/kg) as a sympatholytic to blunt laryngoscopy response when safe. Lidocaine is not recommended.
                                                                                                                                                                                                                                        •  Use rapid-sequence induction (RSI) with hemodynamically neutral agents, such as etomidate or ketamine (now considered safe and may reduce ICP).
                                                                                                                                                                                                                                        • Succinylcholine is preferred for shortened paralysis unless there is a contraindication. Rocuronium is acceptable with awareness of prolonged effect.
                                                                                                                                                                                                                                        • Maintain eucapnia during BVM via waveform capnography.
                                                                                                                                                                                                                                        • Video laryngoscopy is recommended to improve first-pass success and reduce complications.
                                                                                                                                                                                                                                          • After intubation-
                                                                                                                                                                                                                                            • Set ventilator settings for pH 7.3–7.4, PCO2 35–45 mmHg, SpO2 >95%, tidal volume 6-8 cc/kg, and initial PEEP of 5-8 cmH20.
                                                                                                                                                                                                                                            • Reserve hyperventilation (target PCO2 30–35 mmHg) for brief ICP crisis management, paired with ICP lowering therapy (hypertonic saline, mannitol).
                                                                                                                                                                                                                                            • Provide adequate analgesia and sedation to prevent agitation and ICP spikes.
                                                                                                                                                                                                                                              • Propofol + fentanyl is preferred if hemodynamically stable. Consider adding low-dose vasopressor (e.g. norepinephrine) for mild hypotension.
                                                                                                                                                                                                                                              • Use midazolam if significant hypotension.
                                                                                                                                                                                                                                              • Ketamine or dexmedetomidine are useful as adjuncts for patients requiring multiple sedative agents.
                                                                                                                                                                                                                                              •  Delay antihypertensives until after pain/anxiety is addressed to avoid hypotension.
                                                                                                                                                                                                                                              •  Initiate continuous EEG when possible to detect non-convulsive seizures.
                                                                                                                                                                                                                                              • How does this change my practice?

                                                                                                                                                                                                                                                The practical framework provided in this article stresses the importance of individualizing the approach to each brain-injured patient, with the goal of minimizing secondary brain injury. This allows a physician to consider the nuance of pharmacologic strategies (ketamine is OK!), intubation techniques (VL>DL), and post-intubation considerations (sedation first, consider EEG).

                                                                                                                                                                                                                                                Source

                                                                                                                                                                                                                                                Airway Management in Patients With Acute Brain Injury or Ischemia. J Emerg Med. 2025 Jul;74:125-133. doi: 10.1016/j.jemermed.2024.12.015. Epub 2025 Jan 6. PMID: 40348691

                                                                                                                                                                                                                                                The post PODCAST: Airway Management in TBI or Ischemia first appeared on האיגוד הישראלי לרפואה דחופה.

                                                                                                                                                                                                                                                4 min

                                                                                                                                                                                                                                              About מתמחים - האיגוד הישראלי לרפואה דחופה

                                                                                                                                                                                                                                              From the publisher's feed

                                                                                                                                                                                                                                              The Israel Association for Emergency Medicine